Cover Image

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

Background:To investigate tumour biomarker status and efficacy of first-line panitumumab+FOLFIRI for metastatic colorectal carcinoma (mCRC).Methods:154 patients received first-line panitumumab + FOLFIRI every 14 days. Primary end point was objective response rate (ORR). Data were analysed by tumour...

Full description

Saved in:
Bibliographic Details
Main Authors: Karthaus, Meinolf (Author) , Hofheinz, Ralf-Dieter (Author)
Format: Article (Journal)
Language:English
Published: 20 October 2016
In: British journal of cancer
Year: 2016, Volume: 115, Issue: 10, Pages: 1215-1222
ISSN:1532-1827
DOI:10.1038/bjc.2016.343
Online Access:Verlag, Volltext: https://doi.org/10.1038/bjc.2016.343
Verlag, Volltext: https://www.nature.com/articles/bjc2016343
Get full text
Author Notes:Meinolf Karthaus, Ralf-Dieter Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Kelly S. Oliner, Michael Boedigheimer, Brian Twomey, Ying Zhang, Gaston Demonty and Claus-Henning Köhne
Description
Summary:Background:To investigate tumour biomarker status and efficacy of first-line panitumumab+FOLFIRI for metastatic colorectal carcinoma (mCRC).Methods:154 patients received first-line panitumumab + FOLFIRI every 14 days. Primary end point was objective response rate (ORR). Data were analysed by tumour RAS (KRAS/NRAS) and BRAF status, and baseline amphiregulin (AREG) expression.Results:Objective responses occurred more frequently in RAS wild type (WT) (59%) vs RAS mutant (MT) (41%) mCRC and in RAS WT/BRAF WT (68%) vs RAS or BRAF MT (37%) disease. Median response duration was longer in RAS WT (13.0 months) vs RAS MT (5.8 months) (hazard ratio (HR): 0.16). Median progression-free survival was longer in RAS WT vs MT (11.2 vs 7.3 months; HR, 0.37) and was also longer in RAS WT/BRAF WT vs RAS or BRAF MT (13.2 vs 6.9 months; HR, 0.25). Incidence of adverse events was similar regardless of RAS/BRAF status, and no new safety signals were noted. Among patients with RAS WT tumours, ORR was 67% with high AREG expression and 38% with low AREG expression.Conclusions:First-line panitumumab+FOLFIRI was associated with favourable efficacy in patients with RAS WT and RAS WT/BRAF WT vs MT mCRC tumours and was well tolerated.
Item Description:Gesehen am 28.05.2019
Physical Description:Online Resource
ISSN:1532-1827
DOI:10.1038/bjc.2016.343

Similar Items